Hussman Strategic Advisors Inc. Has $1.08 Million Stock Position in Sarepta Therapeutics, Inc. $SRPT

Hussman Strategic Advisors Inc. increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 500.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 63,000 shares of the biotechnology company’s stock after buying an additional 52,500 shares during the quarter. Hussman Strategic Advisors Inc. owned 0.06% of Sarepta Therapeutics worth $1,077,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Ancora Advisors LLC raised its stake in Sarepta Therapeutics by 150.0% during the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 300 shares in the last quarter. Banque Transatlantique SA bought a new stake in shares of Sarepta Therapeutics during the 1st quarter valued at approximately $44,000. Pandora Wealth Inc. acquired a new position in Sarepta Therapeutics during the 1st quarter worth approximately $45,000. Brooklyn Investment Group boosted its position in Sarepta Therapeutics by 450.4% in the first quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 590 shares in the last quarter. Finally, Blue Trust Inc. increased its holdings in Sarepta Therapeutics by 542.3% in the 2nd quarter. Blue Trust Inc. now owns 3,282 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 2,771 shares in the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Down 33.7%

Shares of NASDAQ SRPT opened at $16.20 on Wednesday. The company has a market capitalization of $1.58 billion, a P/E ratio of -18.62 and a beta of 0.51. Sarepta Therapeutics, Inc. has a 52-week low of $10.41 and a 52-week high of $138.81. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. The company’s 50 day moving average price is $20.32 and its 200-day moving average price is $26.28.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.15). Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The firm had revenue of $399.36 million for the quarter, compared to analyst estimates of $331.51 million. During the same quarter last year, the company earned $0.62 earnings per share. The company’s quarterly revenue was down 14.5% compared to the same quarter last year. Equities analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Wall Street Analyst Weigh In

SRPT has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Sarepta Therapeutics in a research note on Tuesday, October 14th. Baird R W downgraded shares of Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 18th. Citigroup assumed coverage on shares of Sarepta Therapeutics in a report on Tuesday, July 22nd. They set a “sell” rating on the stock. Robert W. Baird dropped their price target on shares of Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating for the company in a research note on Tuesday. Finally, Sanford C. Bernstein assumed coverage on shares of Sarepta Therapeutics in a report on Tuesday, July 29th. They set a “market perform” rating and a $13.00 price target on the stock. Seven investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and seven have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $33.67.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.